Research Topics
Genomes and GenesSpecies | Mario ScartozziSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximabM Scartozzi
Department of Medical Oncology, United Hospitals, and Postgraduate School in Medical Oncology, University of Ancona, Ancona, Italy
Ann Oncol 23:1706-12. 2012....
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patientsM Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
Br J Cancer 106:799-804. 2012..We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line bevacizumab...
Epidermal growth factor receptor: a promising therapeutic target for colorectal cancerMario Scartozzi
Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona and Istituto di Anatomia Patologica, Universita Politecnica delle Marche, Ancona, Italy
Anal Quant Cytol Histol 28:61-8. 2006..Moreover, the biological selection of colorectal tumors more likely to benefit from this treatment approach is still to be defined...- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumabM Scartozzi
Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy
Ann Oncol 20:227-30. 2009.... - Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patientsM Scartozzi
Department of Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
Ann Oncol 22:897-902. 2011..Preclinical studies suggested that integrins are relevant for gastric cancer diffusion. We investigated integrins polymorphisms role in determining peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer... - Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsM Scartozzi
Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
Br J Cancer 104:1786-90. 2011..The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab... - Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic targetMario Scartozzi
Clinic of Medical Oncology, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona Italy
Anal Quant Cytol Histol 31:417-23. 2009..To clarify the role of epidermal growth factor receptor (EGFR) promoter methylation in primary colorectal cancers and corresponding metastases and its relationship to EGFR expression... - Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysisMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
BMC Cancer 9:303. 2009..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab... - Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapyMario Scartozzi
Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
J Clin Oncol 25:3930-5. 2007..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan... - Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecanMario Scartozzi
Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
Int J Cancer 127:1941-7. 2010..Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients... - Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1Rossana Berardi
Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy
Expert Opin Pharmacother 10:2245-58. 2009..This review discusses the role of neoadjuvant chemoradiotherapy regimens used in the standard combined modality treatment programs for rectal cancer and focuses on the ongoing research to improve these regimens... - Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practiceMirco Pistelli
Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Ancona, Italy
Tumori 97:275-9. 2011..We retrospectively evaluated the efficacy of FOLFIRI as second-line treatment in advanced gastric cancer patients progressing after platinum-based chemotherapy... - Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patientsMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
PLoS ONE 7:e38192. 2012..The selection tool deriving from this analysis may allow an optimal use of the available treatment strategies in these patients... - Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trialStefano Cascinu
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
Cancer Chemother Pharmacol 68:37-43. 2011..With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C... - Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patientsMario Scartozzi
Clinica di Oncologia, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
Dig Liver Dis 44:74-9. 2012..Retrospective analyses suggested that a pharmacogenetic approach may allow a tailored selection of chemotherapy for metastatic colorectal cancer... - Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature reviewRossana Berardi
Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
Crit Rev Oncol Hematol 69:223-36. 2009..We extensively reviewed the published scientific literature on this topic in order to investigate the clinical and genetic profiling underlying lung cancer in women and to use this information as a tool for medical therapy... - Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?Mario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 6020 Ancona, Italy
Lung Cancer 68:433-7. 2010.... - The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysisMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
Dig Liver Dis 43:194-8. 2011..The benefit of preoperative chemotherapy in patients with initially resectable liver metastases from colorectal cancer is still a matter of debate... - Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcomeRossana Berardi
Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Ancona, Italy
Int J Radiat Oncol Biol Phys 75:1437-43. 2009..To determine the importance of downstaging of locally advanced rectal cancer after neoadjuvant treatment... - The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximabMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
Oncologist 16:53-60. 2011..Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients... - COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatinStefano Cascinu
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
Am J Clin Oncol 30:526-30. 2007..We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer... - Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2Rossana Berardi
Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi G Salesi di Ancona, Medical Oncology Unit, 60020 Ancona, Italy
Expert Opin Pharmacother 10:2467-78. 2009..The present review analyzes the new molecular targets that could be involved in predicting response and prognosis... - Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximabMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Marche Via Conca, Ancona, 60020, Italy
J Transl Med 10:71. 2012..The EGFR pathway activation via the Ras-Raf-MAP-kinase and the protein-serine/threonine kinase AKT could determine resistance to anti-EGFR treatment... - Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancerMario Scartozzi
Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, , Ancona, Italy
Tumori 92:384-8. 2006..CONCLUSIONS: The combination of capecitabine and mitomycin C could represent an effective and manageable treatment option for colorectal cancer patients failing previous chemotherapy regimens... - Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodiesMario Scartozzi
Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
J Clin Oncol 22:4772-8. 2004.... - Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategyMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 71, Ancona, 60020, Italy
Curr Oncol Rep 12:175-85. 2010..Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients... - Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancerMario Scartozzi
AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
Curr Opin Mol Ther 12:361-71. 2010..Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice... - Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patientsMario Scartozzi
Clinica di Oncologia Medica, , Ancona, Italy
Lung Cancer 53:103-9. 2006..031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies... - The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical managementMario Scartozzi
Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Universita Politecnica delle Marche, Ancona, Italy
PLoS ONE 7:e32653. 2012.... - Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapyRossana Berardi
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
Tumori 91:463-6. 2005..The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer... - 5-Fluorouracil pharmacogenomics: still rocking after all these years?Mario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
Pharmacogenomics 12:251-65. 2011..In this article, we will focus on the often contradictory results of these studies... - Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectivesMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
Cancer Treat Rev 35:451-62. 2009..This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research... - Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approachesMario Scartozzi
Clinica di Oncologia Medica, , Ancona, Italy
Cancer Treat Rev 30:451-9. 2004..e., thymidilate synthase that is targeted by 5FU) or to a new class of antineoplastic molecules (i.e., c-erb B-2 targeted by trastuzumab, COX-2 by NSAIDs, matrix metalloproteinases, EGFR and VEGFR by specific inhibitors)... - Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu
Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
Lancet Oncol 9:39-44. 2008..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer... - Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysisMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
J Exp Clin Cancer Res 29:164. 2010..In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome... - Angiogenetic pathway as a therapeutic target in renal cell carcinomaMaristella Bianconi
Medical Oncology Clinic, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy
Anal Quant Cytol Histol 34:15-22. 2012.... - Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensityNicola Battelli
Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Italy
Tumori 97:449-53. 2011..The combination of capecitabine and vinorelbine is a valuable regimen in metastatic breast cancer treatment, even in pretreated patients... - Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitorsRossana Berardi
Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
Anal Quant Cytol Histol 33:196-204. 2011..To verify whether epidermal growth factor receptor (EGFR) status could be considered a prognostic factor and assessment of it an effective tool for planning therapy in patients with non-small cell lung cancer (NSCLC)... - Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic optionsLuca Faloppi
Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
Cancer Treat Rev 37:169-77. 2011..Only recently the molecular targeted drug, Sorafenib, has been introduced among the therapeutic options for these patients... - State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumorsMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Ancona, Italy
Discov Med 11:144-53. 2011..The efficacy profile seems to be promising. However, further studies are needed to define the exact role of IGF-1R inhibitors in clinical practice... - Pancreatic cancer: progress in cancer therapyChiara Pierantoni
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
Crit Rev Oncol Hematol 67:27-38. 2008..New treatment strategies and a more careful evaluation of innovative therapies are clearly needed for this disease. In this review we will focus on treatment strategies both in resectable and advanced pancreatic cancer... - Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literatureRossana Berardi
Medical Oncology Department, University of Ancona, Azienda Ospedaliera Umberto I, Ancona, Italy
Suppl Tumori 2:S45-7. 2003..CONCLUSIONS: Further studies are warranted to identify more satisfactory strategies as well as to identify patients who are more likely to benefit from an adjuvant treatment... - Chemotherapy for advanced gastric cancer: across the years for a standard of careMario Scartozzi
Universita Politecnica delle Marche, Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
Expert Opin Pharmacother 8:797-808. 2007..The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy... - The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?Alessandro Bittoni
Scuola di Specializzazione in Oncologia, Universita Politecnica delle Marche, Via Tronto 10 A, 60100 Ancona, Italy
Crit Rev Oncol Hematol 85:332-41. 2013..Then we identify three main categories of CRCLM patients, providing clinical recommendations for each... - Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practiceMario Scartozzi
Azienda Ospedaliera Ospedali Riuniti-Universita, Clinica di Oncologia Medica, Politecnica delle Marche, Via Conca 60020, Ancona, Italy
Expert Opin Ther Targets 10:281-7. 2006..Moreover, the biological selection of colorectal tumours most likely to benefit from this treatment approach is still to be defined... - Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature reviewRossana Berardi
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Via Conca 71, 60020 Ancona, Italy
Cancer Treat Rev 32:333-47. 2006..In the second part we analysed the new molecular targets developing an hypothesis about the future therapeutics perspectives... - New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocolsRossana Berardi
, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
JOP 6:118-21. 2005 - Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancerRossana Berardi
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
Core Evid 5:61-76. 2010..The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice... - Gastric cancer treatment: a systematic reviewRossana Berardi
Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, 60020 Ancona, Italy
Oncol Rep 11:911-6. 2004..This review will focus on the several treatment modalities available for gastric cancer patients: surgery, adjuvant, neoadjuvant and palliative chemotherapy as well as new target agents... - [Non-small cell lung carcinoma: pathology, biology and prognosis]Federica Freddari
Clinica di Oncologia Medica, , Ancona
Suppl Tumori 3:S3-4. 2004 - Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expressionMario Scartozzi
Department of Clinica di Oncologia Medica, University of Ancona, Ancona, Italy
J Clin Oncol 20:1203-8. 2002..These data suggest that germ-line mutations of the MMR gene can occur in people with MSI-negative tumors. Sensitive clinical criteria and the study of MMR gene expression may be useful to identify this subset of patients... - Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic studyMonica Amati
Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Via Tronto 10 A, Torrette di Ancona, Ancona, Italy
Cancer Epidemiol Biomarkers Prev 17:163-70. 2008..The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations...